Polaryx Therapeutics, Inc. PLYX 深 沪
等待开盘 02-20 09:30:00 美东时间
2.67
-0.220
-7.61%
华盛通- 最 高2.93
- 今 开2.82
- 成交量 62.32万股
- 最 低 2.55
- 昨 收 2.89
- 总市值 0
- 52周最高 48.91
- 市盈率 静 --
- 换手率 Infinity.00%
- 52周最低 2.201
- 委 比 92.39%
- 总股本 --
- 历史最高 48.91
- 量 比 0.05
- 振 幅 13.15%
- 历史最低 2.201
- 每 手 1
- 风险率 13.33%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多What's Going On With Polaryx Therapeutics Stock Wednesday?
Polaryx Therapeutics Inc. (NASDAQ: PLYX) stock fell after a surge due to a major clinical development announcement.
02-18 23:19
Dow Gains 100 Points; Analog Devices Posts Upbeat Q1 Earnings
U.S. stocks traded higher this morning, with the Dow Jones index gaining around...
02-18 22:48
美股牛股 | Polaryx飙升逾64%，药物临床实验推进方面取得显著进展；麦斯莫医疗、以星综合航运均获高额溢价收购
Polaryx飙升逾64%，药物临床实验推进方面取得显著进展；麦斯莫医疗、以星综合航运均获高额溢价收购，隔夜分别大涨34%，25%>>
02-18 18:30
Small Cap Polaryx Picks Research Partner, Stock Surges on Phase 2 Trial Plans
Polaryx Therapeutics (NASDAQ: PLYX) shares rise on selecting research organization for SOTERIA trial to evaluate lead candidate for lysosomal storage disorders.
02-17 23:26
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers American Well (NYSE:AMWL) stock moved upwards by 31.2% to $5.68 during...
02-14 01:05
Polaryx Therapeutics Highlights Late-Breaking Presentation Of New Data For PLX-200, Investigational Therapy For Treatment Of Krabbe Disease At 22nd Annual WORLDSymposium
Polaryx Therapeutics (NASDAQ:PLYX), a clinical-stage biotechnology company developing novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders ("LSDs"), announced that the late-breaking
02-10 21:47
Why STMicroelectronics Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Shares of STMicroelectronics NV (NYSE:STM) rose sharply in pre-market trading a...
02-09 18:56
首日收盘|Polaryx Therapeutics, Inc.收跌22.22%，最新总市值16.57亿美元
Polaryx Therapeutics, Inc.跌22.22%，最新市值16.57亿美元；
02-03 06:00
Polaryx Therapeutics Shares To Start Trading On Nasdaq Under Ticker Symbol PLYX On Feb. 2
Polaryx Therapeutics ("Polaryx" or the "Company") a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric lysosomal
02-02 21:41
